Literature DB >> 16518076

Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts.

Keiko Suzuki1, Sadaaki Takeyama, Yasushi Sakai, Shoji Yamada, Hisashi Shinoda.   

Abstract

Despite the extensive use of bisphosphonates (BPs) in the treatment of metabolic bone diseases associated with increased osteoclastic bone resorption, the precise mechanism of their action on bone metabolism is still unclear. To clarify at which stages of osteoclast differentiation and activation that BPs influence, we examined the osteoclasts generated from mononuclear precursors and osteoclasts in the calvaria by laser scanning confocal microscopy. The studies showed that BPs inhibit lipopolysaccharide- or parathyroid hormone-induced osteoclast differentiation, fusion, attachment, actin ring formation, and activation and that both beta3 integrin and osteopontin have an important role in cytoskeletal rearrangements associated with cell attachment and resorption in osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518076     DOI: 10.1254/jphs.fmj05004x2

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.

Authors:  Tara L Aghaloo; Simon Cheong; Olga Bezouglaia; Paul Kostenuik; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

3.  Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

Authors:  René Rizzoli
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

4.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

Review 5.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

6.  OSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM.

Authors:  Amanda Brown
Journal:  Transl Neurosci       Date:  2012-02-01       Impact factor: 1.757

7.  Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study.

Authors:  A Andriani; M T Petrucci; T Caravita; M Montanaro; N Villivà; A Levi; A Siniscalchi; V Bongarzoni; F Pisani; M De Muro; U Coppetelli; G Avvisati; A Zullo; A Agrillo; D Gaglioti
Journal:  Blood Cancer J       Date:  2012-03-23       Impact factor: 11.037

Review 8.  Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases.

Authors:  Nausicaa Clemente; Davide Raineri; Giuseppe Cappellano; Elena Boggio; Francesco Favero; Maria Felicia Soluri; Chiara Dianzani; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-12-20       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.